Article Text

Download PDFPDF
Review: LABAs are better than leukotriene receptor antagonists when added to inhaled corticosteroids in recurrent asthma

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In patients with recurrent asthma, what is the effectiveness of adding long acting β2 agonists (LABAs) or leukotriene receptor antagonists (LTRAs) to inhaled corticosteroids (ICSs)?

Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006;(4):CD003137.

Clinical impact ratings GP/FP/Primary care âââââââ IM/Ambulatory care âââââââ Allergy & immunology âââââââ Paediatrics âââââââ


Embedded ImageData sources:

Medline, CINAHL, EMBASE/Excerpta Medica, Cochrane Central Register of Controlled Trials, Cochrane Airways Group Specialised Register (to March 2006), hand searches of respiratory journals and meeting abstracts, and bibliographies of relevant published and unpublished studies and reviews.

Embedded ImageStudy selection and assessment:

randomised controlled trials (RCTs) that evaluated the effectiveness of adding LABAs (salmeterol or …

View Full Text


  • Sources of funding: Nederlands Asthma Fonds Netherlands and NHS Research and Development.

  • Reproduced with permission from Evidence-Based Medicine 2007;12:82